当前位置: 首页 > 期刊 > 《中国医学创新》 > 2019年第10期
编号:13384717
雌激素受体拮抗剂对泌乳素腺瘤GH3细胞增殖的影响(5)
http://www.100md.com 2019年4月5日 《中国医学创新》 2019年第10期
     [16] Faraoni E Y,Camilletti M A,Abeledo-Machado A,et al.

    Sex differences in the development of prolactinoma in mice overexpressing hCGβ:role of TGFβ1[J].Journal of Endocrinology,2017,232(3):535-546.

    [17] Hajder M,Hajder E,Dervisefendic M,et al.Prolactinomas in infertile women:clinical and endocrine characteristics before and after 24 months of treatment with bromocriptine[J].Medical Archives,2013,67(3):181-184.

    [18] Filopanti M,Barbieri A M,Angioni A R,et al.Dopamine D2 receptor gene polymorphisms and response to cabergoline therapy in patients with prolactin-secreting pituitary adenomas[J].Pharmacogenomics Journal,2008,8(5):357-363.

    [19] Wu Z B,Zheng W M,Su Z P,et al.Expression of D2RmRNA isoforms and ERmRNA isoforms in prolactinomas:correlation with the response to bromocriptine and with tumor biological behavior[J].J Neurooncol,2010,99(1):25-32.

    [20] Shimazu S,Shimatsu A,Yamada S,et al.Resistance to dopamine agonists in prolactinoma is correlated with reduction of dopamine D2 receptor long isoform mRNA levels[J].European Journal of Endocrinology,2012,166(3):383-390.

    [21] Cao L,Gao H,Gui S,et al.Effects of the estrogen receptor antagonist fulvestrant on F344 rat prolactinoma models[J].

    J Neurooncol,2014,116(3):523-531.

    (收稿日期:2018-09-28) (本文編辑:周亚杰), 百拇医药(朱正凯 林少华 李亮明)
上一页1 2 3 4 5